Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition

References

• Beral V (Collaborative Group on Hormonal Factors in Breast Cancer). Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;50: 1047–59
   Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002;288:321–33
   Google Scholar
• Bergkvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen—progestogen replacement therapy. Am J Epidemiol 1989;130:221–8
   Google Scholar
• Colditz GA, Rosner B. Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone. Am J Epidemiol 1998;147(Suppl):46S
   Google Scholar
• Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen—progestin replacement. Cancer Causes Control 1999;10:253–60
   Google Scholar
• Schairer C, Lubin J, Troisi R, Strugeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen—progestin replacement therapy and breast cancer risk. J Am Med Assoc 2000;283: 485–91
   PubMed Web of Science ®Google Scholar
• Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy of breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328–32
   PubMed Web of Science ®Google Scholar
• Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen—progestin-replacement therapy. Int J Cancer 1999;81:339–44
   PubMed Web of Science ®Google Scholar
• Sturdee DW, MacLennan A.H. Preimum non nocere [Editorial]. Climacteric 2002;5:209–10
   PubMed Web of Science ®Google Scholar
• Schneider HPG. The view of the International Menopause Society on the Women's Health Initiative. Climacteric 2002;5:211–16
   PubMed Web of Science ®Google Scholar
• Letters to JAMA. Risk of postmenopausal hormone replacement therapy. J Am Med Assoc 2002;288:2819–24
   Google Scholar
• Marsden J. Hormone-replacement therapy and breast cancer. Lancet Oncol 2002;3:303–11
   PubMed Web of Science ®Google Scholar
• Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitiative review. Obstet Gynecol 2001;98: 498–508
   Google Scholar
• Sturdee DW. HRT and cancer again [Editorial]. Climacteric 2000;3:1–2
   PubMedGoogle Scholar
• Speroff L. Postmenopausal estrogen—progestin therapy and breast cancer: a clinical response to epidemiological resports. Climacteric 2000;3: 3–12
   PubMedGoogle Scholar
• Genazzani AR. HRT and breast cancer: is there any news? A clinician's perspective. Climacteric 2000;3:13–16
   PubMedGoogle Scholar
• de Ligieres B. Effects of progestogens on the postmenopausal breast [Invited editorial]. Climacteric 2002;5:229–35
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Lee CSL, Sutherland RL. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor a, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 1991;11:5032–43
   Google Scholar
• Lippert C, Seeger H, Wallwiener D, Mueck AO. Comparison of the effects of continuous combined and sequential combined medroxy-progesterone acetate—estradiol treatment on the proliferation of MCF-7 cells. Climacteric 2000;3: 271–7
   PubMedGoogle Scholar
• Andreotti PE, Thornthwaite JT, Morse IS. ATP tumor chemosensitivity assay. In Stanley PE, Kricka u, eds. Bioluminescence and aemi-luminescence: Current Status. Chichester: J. Wiley & Sons, 1991:417–20
   Google Scholar
• Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat 1998;48:221–9
   Google Scholar
• Amato P, Christophe S, Mellon PL. Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. Menopause 2002;9: 145–50
   Google Scholar
• Lippert TH, Seeger H, Mueck AO. Pharmaco-logy and toxicology of different estrogens. Gynecol Endocrinol 2001;15 ( Suppl4 ) :26–33
   Google Scholar
• Stanzcyk FZ. Estrogens used for replacement therapy in postmenopausal women. Gynecol Endocrinol 2001;15(Suppl 4):17–25
   Google Scholar
• Maxson WS, Hargrove JT. Bioavailability of oral micronized progesterone. Fertil Steril 1985;44: 622–6
   PubMed Web of Science ®Google Scholar
• Svensson LO, Johnson SH, Olsson SE. Plasma concentrations of medroxyprogesterone acetate, estradiol and estrone following oral admini-stration of Klimaxil®, Trisequence/Provera®, and Divina®. A randomised, single-blind, triple cross-over bioavailability study in menopausal women. Maturitas 1994;18:229–38
   Google Scholar
• Stanczyk FZ, Brenner PF, Mishell DR, Ortiz A, Gentzschein EKE, Goebelsmann U. A radio-immunoassay for norethindrone (NET): measurement of serum net concentrations following ingestion of NET-containing oral con-traceptive steroids. Contraception 1978;18: 615–33
   PubMed Web of Science ®Google Scholar
• Blakenstein MA, Maitimu-Smelle I, Donker GH, Daroszewski J, Milewicz A, Thijssen JH. On the significance of in situ production of oestrogens in human breast cancer tissue. J Steroid Biochem Mol Biol 1992;41:891–6
   PubMed Web of Science ®Google Scholar
• Klein R. The composition of premarin. Int J Fertil 1998;43:223
   Google Scholar
• Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998; 69:963–9
   PubMed Web of Science ®Google Scholar
• Hargreaves DF, Knox F, Swindell R, Potten CS, Bundred NJ. Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy. Br J Cancer 1998;78: 945–9
   Google Scholar
• Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxy-progesterone acetate is associated with increased epithelial proliferation in the normal post-menopausal breast. J Clin Endocrinol Me tab 1999;84:4559–65
   PubMed Web of Science ®Google Scholar
• Wang S, Counterman u, Haslam SZ. Proges-terone action in normal mouse mammary gland. Endocrinology 1990;127:2183–9
   Google Scholar
• Woodward TL, Xie JW, Haslam SZ. The role of mammary stroma in modulating the proliferative response to ovarian hormones in the normal mammary gland. J Mammary Gland Biol Neoplasia 1998;3:117–31
   PubMed Web of Science ®Google Scholar
• Noel A, Foidart JM. The role of stroma in breast carcinoma growth in vivo. J Mammary Gland Biol Neoplasia 1998;3:215–25
   PubMed Web of Science ®Google Scholar